Riemann Annika, Blaschke Martina, Jauho-Ghadimi Annukka, Siggelkow Heide, Gollisch Katja Susanne Claudia
Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075 Göttingen, Germany.
MVZ Endokrinologikum Göttingen, 37075 Göttingen, Germany.
J Clin Med. 2022 Jul 24;11(15):4294. doi: 10.3390/jcm11154294.
Non-alcoholic fatty liver disease (NAFLD) is a common yet little recognized health problem in women with polycystic ovary syndrome (PCOS). In a retrospective setting, we investigated the effects of metformin treatment on the hepatic steatosis index (HSI) as a readily available biomarker panel for NAFLD. HSI values of >36 are considered to be highly suggestive for NAFLD. In our cohort, HSI values indicating NAFLD were found in 60/81 (74.1%) women at baseline. The mean HSI improved significantly after the metformin treatment from 43.2 ± 1.0 to 41.0 ± 1.1. Subgroup analyses of non-obese (body mass index (BMI) < 30 kg/m2), obese (BMI 30−35 kg/m2) and very obese (BMI > 35 kg/m2) women yielded mean baseline HSI values of 35.5 ± 4.5, 41.2 ± 2.7 and 51.2 ± 4.7, respectively. A significant improvement in the HSI of 1.5 ± 2.1 was observed after metformin treatment in non-obese women but not in the obese subgroups. The data suggest a new aspect of metformin treatment in non-obese PCOS patients, namely, a possible improvement in NAFLD. This study highlighted hepatic steatosis as a common comorbidity in PCOS patients that can severely affect their long-term health, and therefore, deserves more attention in the management of PCOS patients.
非酒精性脂肪性肝病（NAFLD）是多囊卵巢综合征（PCOS）女性中常见但却鲜为人知的健康问题。在一项回顾性研究中，我们调查了二甲双胍治疗对肝脂肪变性指数（HSI）的影响，HSI是一种现成的用于NAFLD的生物标志物组。HSI值>36被认为高度提示NAFLD。在我们的队列中，60/81（74.1%）名女性在基线时的HSI值表明患有NAFLD。二甲双胍治疗后，平均HSI从43.2±1.0显著改善至41.0±1.1。对非肥胖（体重指数（BMI）<30kg/m²）、肥胖（BMI 30 - 35kg/m²）和非常肥胖（BMI>35kg/m²）女性的亚组分析显示，基线时平均HSI值分别为35.5±4.5、41.2±2.7和51.2±4.7。二甲双胍治疗后，非肥胖女性的HSI显著改善了1.5±2.1，而肥胖亚组则未改善。这些数据提示了二甲双胍治疗非肥胖PCOS患者的一个新方面，即可能改善NAFLD。本研究强调了肝脂肪变性是PCOS患者中常见的合并症，可严重影响其长期健康，因此，在PCOS患者的管理中值得更多关注。
